Longeveron Inc. LGVN

LGVN Company Overview

Longeveron Inc. is a clinical-stage biotechnology company focused on regenerative medicine and cellular therapies. The company develops investigational treatments derived from medicinal signaling cells (MSCs), with an emphasis on aging-related and life-threatening conditions. Longeveron operates primarily within the biotechnology, regenerative medicine, and cell therapy industries, targeting unmet medical needs in areas such as Alzheimer’s disease, pediatric hypoplastic left heart syndrome (HLHS), and acute respiratory distress syndrome (ARDS). The company’s primary value driver is the development and commercialization potential of its proprietary stem cell-based therapeutic platform.

The company was founded in 2014 and is headquartered in Miami, Florida. Longeveron evolved from academic and clinical research led by physicians and scientists specializing in regenerative medicine and cardiovascular disease. Its strategic positioning is tied to its intellectual property portfolio, clinical trial development capabilities, and focus on aging-related disorders where few approved regenerative therapies currently exist. The company has also pursued orphan disease opportunities and FDA regulatory pathways intended to accelerate development timelines for select indications.